DLK Investment Management LLC Has $4.15 Million Position in Becton, Dickinson and Company (NYSE:BDX)

DLK Investment Management LLC cut its position in Becton, Dickinson and Company (NYSE:BDX) by 4.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,301 shares of the medical instruments supplier’s stock after selling 917 shares during the quarter. Becton, Dickinson and Company accounts for about 1.7% of DLK Investment Management LLC’s holdings, making the stock its 26th biggest holding. DLK Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $4,152,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. Ieq Capital LLC boosted its position in Becton, Dickinson and Company by 22.0% during the 2nd quarter. Ieq Capital LLC now owns 9,238 shares of the medical instruments supplier’s stock worth $2,159,000 after buying an additional 1,668 shares during the period. AE Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 36.2% during the second quarter. AE Wealth Management LLC now owns 2,482 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 660 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Becton, Dickinson and Company by 7.3% during the second quarter. Sei Investments Co. now owns 222,580 shares of the medical instruments supplier’s stock worth $52,016,000 after purchasing an additional 15,193 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Becton, Dickinson and Company by 12.1% in the second quarter. Thrivent Financial for Lutherans now owns 13,806 shares of the medical instruments supplier’s stock worth $3,227,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Summit Trail Advisors LLC increased its holdings in Becton, Dickinson and Company by 5.3% in the second quarter. Summit Trail Advisors LLC now owns 1,422 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 71 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on BDX shares. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Trading Up 0.5 %

NYSE BDX opened at $237.57 on Monday. The stock has a market capitalization of $68.90 billion, a P/E ratio of 40.00, a P/E/G ratio of 1.69 and a beta of 0.39. The business has a 50 day simple moving average of $227.07 and a 200 day simple moving average of $232.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.42 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were issued a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.75%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 638 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now directly owns 14,217 shares in the company, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,747 shares of company stock valued at $1,949,520 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.